A Phase III, Randomized, Double-Blind Placebo Controlled Study of the Probiotic Preparation VSL#3® Versus Placebo in the Prevention of Acute Enteritis in Patients Receiving Concurrent Chemotherapy and Pelvic Radiation Therapy
OBJECTIVES:
Primary
- To determine whether live freeze-dried lactic acid bacteria probiotic (VSL#3®) is
effective in reducing the acute treatment-related bowel function disturbances, as
measured by the FACIT-D diarrhea subscale score in patients receiving concurrent
chemotherapy and pelvic RT as adjuvant or primary treatment for malignancy.
Secondary
- To determine whether VSL#3® can reduce chronic treatment-related bowel dysfunction
following completion of therapy.
- To examine whether VSL#3® appears to have an impact on disease-free survival.
- To bank blood products for future studies. (exploratory)
- To characterize changes in the fecal microbiota and examine for correlation with
treatment assignment and symptom scores. (exploratory)
OUTLINE: This is a randomized, double-blind, placebo-controlled study. Patients are
stratified according to site of primary tumor (rectum/anus vs other), history of anterior
resection of the rectum (yes vs no), total planned cumulative dose (including boost of
external-beam radiotherapy [RT] or brachytherapy) (4,500-5,350 cGy vs > 5,350 cGy), and use
of intensity-modulated RT [IMRT] for pelvic RT (yes vs no). Patients are randomized to 1 of
2 treatment arms.
- Arm I: Patients receive live freeze-dried lactic acid bacteria probiotic (VSL#3®)
orally (PO) 3 times a day during RT (5-8 weeks) and for 2 weeks after completion of RT.
- Arm II: Patients receive placebo PO 3 times a day during RT (5-8 weeks) and for 2 weeks
after completion of RT.
Patients self-report symptoms using the FACIT-D, PBFQ, PRO-CTCAE, and Uniscale/fatigue
weekly during RT, for 2 weeks after completion of RT, and at 12 months following the
completion of RT.
Blood and stool samples may be collected from some patients for correlative studies.
Interventional
Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Supportive Care
Average area under the curve (AUC) of the FACIT-D diarrhea subscale score assessed weekly during treatment and for two weeks following the completion of RT
No
Robert C. Miller, MD
Principal Investigator
Mayo Clinic
Unspecified
CDR0000716291
NCT01473290
December 2011
Name | Location |
---|